Search the Newsreel

Novavax Inc (NVAX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Novavax Inc (NVAX), identifying its major institutional holders. Key information includes the top shareholders like Shah Capital Management, BlackRock, and State Street, and a breakdown of shareholder types. It also provides a historical overview of institutional shareholdings …

Novavax Inc (NVAX) Cash Flow

This article provides a detailed cash flow statement for Novavax Inc (NVAX), including operating, investing, and financing cash flows presented quarterly and annually. It outlines key financial metrics and defines terms like operating cash flow, investing cash flow, financing cash flow, and free cash …

Novavax Inc (NVAX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a detailed revenue breakdown for Novavax Inc (NVAX) for FY2025, categorized by business segments and regional contributions. It shows that product sales account for 60.97% of revenue, with licensing and royalties making up 39.03%. Regionally, Canada is the largest revenue contributor …

NVAX|Novavax Inc|Price:7.460|Chg%:-0.365

Novavax Inc. (NVAX) shows relatively stable fundamentals and high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. The stock price is expected to remain stable in the medium term, trading sideways between support and resistance levels. Institutional …

Novavax Inc (NVAX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Novavax Inc (NVAX), detailing its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. As of July 24, 2026, NVAX had a price momentum score of 4.46 and was trading …

(NVAX) Price Dynamics and Execution-Aware Positioning

The article provides an AI-driven analysis of Novavax Inc. (NVAX) stock, highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents multiple institutional trading strategies including position trading, momentum breakout, and risk hedging, along with specific entry, target, and stop-loss levels. …

Novavax Inc (NVAX) Institutional Confidence

Novavax Inc (NVAX) has an institutional shareholding score of 7.00, placing it in the top quartile of the Biotechnology & Medical Research industry. Institutional investors collectively hold 77.98% of the shares, a quarter-over-quarter increase of 22.65%. Philippe Laffont is the largest institutional shareholder, with …

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

Novavax (NVAX) has been a frequently searched stock on Zacks.com, prompting an analysis of factors influencing its near-term performance. Despite a recent -10.3% return over the past month, the stock holds a Zacks Rank #1 (Strong Buy) due to positive earnings estimate revisions. While …

Novavax Inc (NVAX) Fundamental & Financial Data

This article provides fundamental and financial data for Novavax Inc (NVAX), including its current stock price, market capitalization, P/E ratio, and recent news. As of the update, NVAX is trading at $7.95 with a market cap of $1.33 billion. The article also lists recent …

Novavax, Inc. (NVAX) Stock Analysis: Potential Upside of 79.10% Amidst Challenging Financial Metrics

Novavax (NVAX) shows a potential upside of 79.10% despite significant financial challenges, including a 79.10% revenue decline and negative EPS. The biotechnology firm specializes in vaccines like Nuvaxovid and the R21 Matrix-M malaria vaccine, maintaining investor interest due to its strategic market position. Analyst …

Novavax Inc. stock underperforms Monday when compared to competitors

Novavax Inc. (NVAX) shares fell 4.02% to $7.88 on Monday, underperforming the broader market. This drop marked the stock's third consecutive day of losses, despite the NASDAQ Composite Index and Dow Jones Industrial Average also experiencing declines.

NVAX stock trades in a wide range as Novavax works through Covid vaccine transition

Novavax (NVAX) navigates a transition from pandemic-era Covid revenues to a commercial market, leading to wide stock trading ranges. The company reported $0.9 billion in revenue for 2024, down from $1.0 billion in 2023, and forecasts at least $0.8 billion for 2025 by focusing …

Novavax Inc. stock underperforms Thursday when compared to competitors

Novavax Inc.'s (NVAX) stock fell 2.25% on Thursday, closing at $8.24, even as the broader market indexes also experienced declines. This performance left Novavax 31.16% below its 52-week high reached in February.

Novavax-Aktie Prognose: Sollten Sie jetzt kaufen?

NVAX Prognose — Kursziel für 2027

Resultados de Novavax en el 1T 2026: los ingresos por asociaciones se disparan

Informe de resultados: Novavax supera previsiones en el 1T 2026 y su acción se dispara

Novavax eleva previsión de ingresos gracias a acuerdos sobre vacunas y sus acciones se disparan

Resultados financieros de Novavax, Inc. – NASDAQ:NVAX

Novavax, Inc. : Consenso de Precios Objetivo y Recomendaciones de los Analistas | NVAX | US6700024010